İnci KAZKAYASI, Sevgi UĞUR MUTLUAY, Elif ÇINAR, Gül YALÇIN ÇAKMAKLI, Bülent ELİBOL, Banu Cahide TEL, Gökçen TELLİ, Esen SAKA

Higher alpha-synuclein aggregate density does not lead to more severe dopaminergic cell loss in the AAV-mediated overexpression model of Parkinson’s Disease: A timecourse study

Pathological intracellular aggregation of alpha-synuclein (a-syn) is the hallmark of Parkinson’s disease(PD). Our aim is to explore the outcomes of long-term a-syn pathology with its functional correlates in the PD modelby AAV (adeno-associated virus)-mediated a-syn overexpression in substantia nigra (SN). Female Wistar rats (220-260g) received a unilateral injection of AAV-human-a-syn or green fluorescent protein (GFP) gene into the SN. The animalswere tested for motor functions with cylinder test at 8, 12 weeks or 9 months post-injection. The intensity of a-synaccumulation or GFP in striatum and dopaminergic neuronal loss in SN, dopaminergic terminal loss in striatum andsynaptic integrity were analyzed by a-syn, GFP, tyrosine hydroxylase (TH) and synaptophsin immunohistochemistry,respectively. At all time-points, AAV-human-a-syn injected animals displayed more motor dysfunction and THpositivecell loss compared to AAV-GFP injected group. A-syn immunoreactivity was present in the nigral neurons aswell as the striatal terminals in all animals that received AAV-a-syn. Striatal TH density analysis showed a decrease inboth 12-weeks and 9 months a-syn groups compared to controls. However, TH-positive neuron count was lower in 9-months group compared to 12-weeks group. Hence, the motor performance of 9-month group showed an improvementwhich may be a sign of a compensatory mechanisms against a-syn-induced neurodegeneration. The findings of thisstudy implicate that higher a-syn density in SN does not always lead to worse motor function or more severedopaminergic cell loss. This may support the hypothesis that a-syn aggregates are the end-product of a cellular defensemechanism rather than being causative pathology.

PDF

___

[1] Chartier S, Duyckaerts C. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? Cell Tissue Res. 2018; 373(1): 149-60. [CrossRef]
[2] Titova N, Schapira AHV, Chaudhuri KR, Qamar MA, Katunina E, Jenner P. Nonmotor Symptoms in Experimental Models of Parkinson's Disease. Int Rev Neurobiol. 2017; 133: 63-89. [CrossRef]
[3] Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Höglinger GU. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Neuropharm. 2015; 95: 367-76. [CrossRef]
[4] Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002; 22(7): 2780-91. [CrossRef]
[5] Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012; 45(3): 939-53. [CrossRef]
[6] Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One. 2013; 8(11): e81426. [CrossRef]
[7] Oliveras-Salva M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dosedependent neurodegeneration. Mol Neurodegener. 2013; 8: 44. [CrossRef]
[8] Van der Perren A, Van den Haute C, Baekelandt V. Viral vector-based models of Parkinson's disease. Curr Top Behav Neurosci. 2015; 22: 271-301. [CrossRef]
[9] Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun. 2015; 3: 46. [CrossRef]
[10] Ulusoy A, Decressac M, Kirik D, Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res. 2010; 184: 89-111. [CrossRef]
[11] Mutluay SU, Çınar E, Yalçın Çakmaklı G, Ulusoy A, Elibol B, Tel BC. Modelling Non-motor Symptoms of Parkinson’s Disease: AAV Mediated Overexpression of Alpha-synuclein in Rat Hippocampus and Basal Ganglia. Turk J Neurol. 2020; 26(4): 322-329. [CrossRef]
[12] Albert K, Voutilainen MH, Domanskyi A, Airavaara M. AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. Genes (Basel). 2017; 8(2): 63. [CrossRef]
[13] Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alphasynuclein. PLoS One. 2011; 6(3): e17698. [CrossRef]
[14] Landeck N, Buck K, Kirik D. Toxic effects of human and rodent variants of alpha-synuclein in vivo. Eur J Neurosci. 2017; 45(4): 536-547. [CrossRef]
[15] Cinar E, Yalcin-Cakmakli G, Saka E, Ulusoy A, Yuruker S, Elibol B, et al. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy? Exp Neurol. 2020; 330: 113357. [CrossRef]
[16] Albert K, Voutilainen MH, Domanskyi A, Piepponen TP, Ahola S, Tuominen RK, et al. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. J Neurosci Res. 2019; 97(3): 346-61. [CrossRef]
[17] Delenclos M, Faroqi AH, Yue M, Kurti A, Castanedes-Casey M, Rousseau L, et al. Neonatal AAV delivery of alphasynuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun. 2017; 5(1): 51. [CrossRef]
[18] Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007; 130(Pt 3): 799-815. [CrossRef]
[19] Paxinos G WC. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition: AcademicPress; 2006.
[20] Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7): 671-5. [CrossRef]